Safety and Efficacy of Filgotinib: Up to 4-Year Results From an Open-Label Extension Study of Phase 2 Rheumatoid Arthritis Programs
J Rheumatol. 2021 Feb 1:jrheum.201183. DOI: 10.3899/jrheum.201183.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
J Rheumatol. 2021 Feb 1:jrheum.201183. DOI: 10.3899/jrheum.201183.
ACR Open Rheumatol. 2021 Feb 11.
Arthritis Res Ther. 2021;23(1):53.
Ann Rheum Dis. 2021 Jan 15:annrheumdis-2020-219213.
Mod Rheumatol 2021;26:1–16.
PLoS ONE 2021;16(1):e0244187
Semin Arthritis Rheum. 2021 Feb;51(1):278-284
Arthritis Res Ther 2021;23(1):3.
Ann Rheum Dis. 2021 Jan 27:annrheumdis-2020-219214
https://pubmed.ncbi.nlm.nih.gov/33549192/
Bimekizumab therapy was associated with a rapid and sustained improvement in PASI response and IGA score in patients with moderate to severe plaque psoriasis. Dual inhibition of IL-17A/F with bimekizumab can affect a more durable response in PsO patients than sole IL-17A inhibition. Gordon et al. compared the safety and efficacy of two different maintenance dosing schedules, in addition to the effects of treatment withdrawal in the 52-week BE READY trial.